The current study demonstrated that itaconate could attenuate neuroinflammation and exert dopamine neuroprotection in PD through inhibiting the NLRP3 inflammasome, proving that itaconate can be used as a promising therapeutic drug for treating PD in the future. This evidence concerns the gene NLRP3 and Parkinson disease.